Kornimate/medical-research-clean huggingface dataset:
billroth ii with braun anastomosis after radical distal gastrectomy for gastric cancer

Conditions: Gastric Cancer; Surgery; Anastomosis; Gastrostomy

Summary: the primary aim of this trial is to rigorously evaluate the comparative benefits and potential risks associated with billroth ii reconstruction with braun anastomosis versus billroth ii reconstruction alone following distal gastrectomy with d2 lymphadenectomy in patients diagnosed with gastric cancer. this assessment focuses on delineating the therapeutic efficacy, safety profile, and overall clinical outcomes of these two surgical approaches in treating this condition.


Eligibility criteria:
inclusion criteria to be enrolled, participants must be phase i-iii patients with initial treatment of radical distal gastrectomy and satisfying the following inclusion criteria: 1. histologically proven stage i-iii gastric cancer, evaluated as radically resectable 2. no synchronous or metachronous cancers 3. patients have signed informed consent forms 4. age 18-80 years old 5. no malfunction of cardio-pulmonary, liver, and kidney, ecog score 0-1 6. no emergency surgery needed exclusion criteria patients will be excluded according to the following criteria: 1. pregnant or lactating women 2. distant metastasis to the liver, lung, bone, supraclavicular lymph nodes, pelvic, or ovarian species and peritoneal dissemination 3. ascites or cachexia 4. suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, poorly controlled hypertension or diabetes 5. participation in other clinical trials 4 weeks before the enrollment of this trial or still participating in other trials 6. mental illness 7. surgical history whose influence has not been eliminated 8. history of another gastric or esophageal malignancy, including stromal tumor, sarcoma, lymphoma, and carcinoid 9. active infection with a fever of over 38°c 10. poor compliance 11. not suitable for this trial because of other clinical or laboratory conditions determined by the researchers

Keywords: gastric cancer gastrostomy billroth ii braun anastomosis
clinical comparative study to validate performance of safesed prototype monitoring endoscopy under sedation

Conditions: Apnea

Summary: safesed prototype monitors respiratory parameters by tracking chest movements with optical and accelerometer markers. the respiratory parameters are compared to respiratory parameters measured by a spirometer and a capnograph.

patients performing endoscopy procedures under sedation at the gastro clinic will be monitored by safesed in addition to being monitored by capnography, used by an anaesthetist. all patients will be monitored using the same two techniques (safesed and capnography). no clinical decisions will be made based upon the data generated by the safesed system. the data from all sources will be compared (post factum) to validate safesed performance. the data collected on the safesed prototype will not be used for treatment of the patient. the comparative analysis will be free vto be used by the sponsor.

Eligibility criteria:
inclusion criteria: * class 1-3 per american society anesthesiologists physical status classification * subject signed informed concent form exclusion criteria: * pregnancy * unresolved pulmonary infection requiring active treatment * chronic pulmonary disease * any othe medical condition, that treating physician determines participating in the study is unadvisable
exploration of gait biomechanics and muscle pain of the lower extremity

Conditions: Pain, Acute

Summary: this interventional study aims to test gait biomechanics in healthy individuals with and without experimental muscle pain in the lower extremities. the study aims to: a) examine how experimental muscle pain in different types of muscles (ankle plantar-flexion, knee extension, and flexion muscles) affects kinematics, kinetics, and muscle activation participants will receive six muscle injections: a) hypertonic saline (painful condition) and b) isotonic saline (control condition) in 1) m. gastrocnemius, 2) m. semitendinosus, and 3) m. biceps femoris.

the proposed study will be a randomized, crossover design in which experimental pain will be induced in healthy subjects using hypertonic saline injections to three muscles of the lower extremities: the gastrocnemius muscle, the vastus medialis muscle, and the semitendinosus muscle. participants will be block-randomized to receive an injection in each of the three muscles and will receive either the painful or control condition first for each muscle. the participant will always be blinded to the type of injection received. following the injection, there will typically be a 15-minute window of pain (45). within this timeframe, motion capture will be carried out for both the control and painful conditions. during motion capture, the participants will perform multiple walking trials of approximately 10 meters. the participants will be equipped with electromyography (emg) sensors on key muscles of the lower extremities. the participants will be asked for nrs ratings every 30 seconds throughout the 15 minutes with expected pain. there will be a 15-minute washout between the muscle injections.

Eligibility criteria:
inclusion criteria: * healthy men and women aged 18-45 years exclusion criteria: * pregnancy * drug addiction, defined as the use of cannabis, opioids, or other drugs * previous or current neurologic or musculoskeletal illnesses * current pain * lack of ability to cooperate

Keywords: musculoskeletal pain healthy participants biomechanics
cosmetic outcomes with tissue adhesive (2-octylcyanoacrylate) or staples in repeated cesarean section

Conditions: Cesarean Section

Summary: recent clinical trials were developed to test the outcomes of skin closure with tissue adhesive, staples and monofilament synthetic suture after cesarean section with pfannenstiel incision: both clinical outcomes such as blood loss, surgical site infection, length of postpartum hospitalization, or wound disruption, as well as patient and observer scar assessment scale (posas) scores 8 weeks after surgery, were comparable between these different skin closure methods. despite the available studies are often based on robust methodologies and appropriate assessment scales, most of them were aimed to evaluate cosmetic outcomes in primary cesarean section, whereas data analyses published so far do not allow to draw a firm conclusion about repeated cesarean sections. based on these elements, the aim of this study is to evaluate cosmetic outcomes after skin closure of pfannenstiel incision with tissue adhesive or staples in a selected population undergoing repeated cesarean section.


Eligibility criteria:
inclusion criteria: * previous cesarean section with pfannenstiel incision (regardless of the indication, emergency/urgency, weeks of pregnancy and years passed from the previous cesarean section) * maternal age 18-45 years * singleton pregnancy at 37-41 weeks of gestation (based on first-trimester ultrasound) with a viable fetus exclusion criteria: * history of keloids * previous transversal suprapubic scars * clinical signs of infection and/or tattoos in the area to be studied * known patient hypersensitivity to any of the suture materials used in the protocol * bmi below 20 or above 30 * any medical disorder that could affect wound healing, including severe malnutrition, conditions requiring chronic corticosteroid use or immune suppressant, uncontrolled diabetes mellitus (defined as hemoglobin a1c \> 6%, unbalanced daily glucose measurements, and fasting glucose \>95 mg/dl).

Keywords: cesarean delivery cosmesis healing skin closure scar assessment scales
botulinum toxin effects on plantar ulcer recurrence

Conditions: Diabetes Mellitus; Peripheral Neuropathy; Plantar Ulcers

Summary: the purpose of this grant is to collect pilot data to assess the amount of botulinum toxin that needs to be injected into the calf muscles of subjects with diabetes mellitus, peripheral neuropathy, and a plantar ulcer to decrease muscle strength. we hypothesize that a decrease in plantar flexor muscle strength will temporarily decrease plantar pressure. the decrease in plantar pressure will provide temporary protection to the new tissue as it gains tolerance to high stress with the long term potential outcome as a decrease in the ulcer recurrence rate.

please read "brief summary"

Eligibility criteria:
inclusion criteria: * diagnosis of diabetes mellitus and determination of diminished or absent plantar sensation * a recurrent forefoot plantar ulcer; at least the second occurrence of a plantar ulcer or a previous failure to heal a plantar ulcer with reasonable treatment intervention (total contact casting, off loading boot, molded ankle foot orthotic, gillette, or therapeutic footwear modifications) * ambulatory exclusion criteria: * active infection in the involved foot * previous botulinum toxin injections * ulcers on the dorsal surface of the foot * ankle-brachial index \<0.45 * history of cerebral vascular accident or other neurological problems complicating their rehabilitation * women of childbearing years unless pregnancy test is agreed upon, completed, and negative and agree to use some form of contraception during the study. * current drug therapy that includes an anticoagulant * history of a neuromuscular disease, except peripheral neuropathy as a result of diabetes mellitus

Keywords: diabetes mellitus plantar ulcers peripheral neuropathy
parallel comparison of 18 gene classifiers and oncotype dx (nanostring)

Conditions: Breast Cancer; Recurrence

Summary: a recurrence index for distant recurrence (ri-dr), an 18-gene-based clinical-genomic model, has been developed for early-stage breast cancer (ebc). in this study, investigators compared the prognostic performance of the ri-dr with the oncotype dx (odx) recurrence score (rs) for any recurrence risk type.

with improved diagnosis, breast cancer can now be detected at early stages, thus improving survival rates. however, overtreatment is common; considering that the risk of recurrence is low, patients may suffer from side effects without receiving the full benefits of adjuvant therapies. to overcome the imprecision of prognosis based on clinicopathologic factors, genomic tests for breast cancer prognosis, such as the oncotype dx® (odx), mammaprint®, and endopredict® assay kits, are frequently utilized. these multigene panels were development based on caucasian populations, and may not suitable to asian population due to the differences in the incidence and lifestyle of breast cancer patients from different ethic backgrounds. to fiil this gap, an 18-gene classifier (18-gc) based on the gene-expression profiling of chinese breast cancer patients was developed in the current study, investigators combined clinical variables and genetic information to generate a clinical-genomic model: ri-dr, a recurrence index for distant recurrence (based on a genomic model and 6 clinical variables: age, tumor size, lymph node status, estrogen receptor status, lymphovascular invasion, tumor grading). by using tissues that have been tested with odx, in this study, investigators evaluated the performance of the ri-dr model with that of the odx assay in the prognosis assessment of a cohort of patients from taiwan.

Eligibility criteria:
inclusion criteria: 1. patients who have performed (oncotype dx) genetic testing methods before june 30, 2017. 2. surgery (mastectomy or breast preservation) as the first treatment. 3. er or pr ihc positive 4. her2 negative 5. n0-n1 patient 6. available with ffpe tumor tissue exclusion criteria: 1. t3-t4 or n2-n3 2. with distant metastasis before surgery 3. preoperative chemotherapy / radiotherapy 4. insufficient ffpe tumor samples

Keywords: breast cancer distant recurrence nanostring gene-expression profiling prognosis locoreginal recurrence
persistent postpartum cardiovascular dysfunction in patients with preeclampsia

Conditions: Preeclampsia Severe or Mild; Cardiac Complication

Summary: the investigators plan to enroll women with pe prospectively to evaluate incremental cardiovascular risk in those who have pe with severe features. this study includes detailed echocardiographic evaluation at several time points. with the current proposal, the investigators aim to collect blood to evaluate several biomarkers to determine if there is a correlation with short and medium-term cardiovascular risk. this opens the door to earlier detection, treatment and improved cardiovascular outcomes.

preeclampsia (pe) is a multi-system progressive disorder affecting up to 8% of pregnancies. epidemiologic studies have shown a significant association between pe and future cardiovascular disease (cvd) in women. despite recognition of this relationship, there are no good markers to help determine which women are at highest risk, in particular as this relates to long-term cardiovascular risk, the number one cause of mortality in u.s. born women. as such, the study of pe and cardiovascular outcomes, in particular to identify early markers for the development of late cvd, provide insight into critical opportunities for early treatment and modification of disease trajectory in women. the investigators plan to enroll women with pe prospectively to evaluate incremental cardiovascular risk in those who have pe with severe features. this study includes detailed echocardiographic evaluation at several time points. with the current proposal, the investigators aim to collect blood to evaluate several biomarkers to determine if there is a correlation with short and medium-term cardiovascular risk. this opens the door to earlier detection, treatment and improved cardiovascular outcomes. the investigators hypothesize that preeclampsia with severe features confers a much higher risk of cardiovascular impairment compared to milder form of preeclampsia and healthy controls. if the hypothesis proves correct, these findings may change clinical practice by warranting routine echocardiogram for these patients for early recognition, intervention and treatment of cardiac dysfunction.

Eligibility criteria:
inclusion criteria: * females older than 18 years of age * singleton pregnancy * the patient is physically and mentally able to understand the informed consent and is willing to participate in this study * able to speak english * must meet one of the population categories, until each group has reached 20 subjects exclusion criteria: * multiple gestation * history of chronic hypertension or cardiac disease including but not limited to history of heart arrhythmias, congenital heart disease, and use of any cardiac medication (such as beta blockers, ace inhibitors, calcium channel blockers) prior to pregnancy. * history of medical problems that may contribute to cardiac dysfunction, including but not limited to chronic hypertension, poorly controlled hyperthyroidism and diabetes mellitus.
intravenous transplantation of mesenchymal stem cell in patients with als

Conditions: Amyotrophic Lateral Sclerosis

Summary: als is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). als is the most common of the five motor neuron diseases.riluzole (rilutek) is the only treatment that has been found to improve survival but only to a modest extent. it lengthens survival by several months, and may have a greater survival benefit for those with a bulbar onset. it also extends the time before a person needs ventilation support.stem cell transplantation is a new hopeful way to improve the patients conditions and reduce the period of disabilities.

in this study our purpose is to evaluate the safety of intraventricular injection of bone marrow derived mesenchymal stem cell.the patients who are eligible,underwent bone marrow aspiration.after cell separation and preparation,the patients underwent mesenchymal stem cell intraventricular injection by stereotaxis.after injection he will be under observed in icu to monitor the adverse events(allergic and neurological side effects).patients are followed 1th,3th ,6th and 12 months after injection and each time these parameters are checked:als-frs,emg-ncv,fvc,side effect check list.

Eligibility criteria:
inclusion criteria: * - age:18-65 * both gender * duration of disease\<2 years * fvc\>40% als-frs\>26 exclusion criteria: * - neurological and psychiatric concomitant disease * concomitant systemic disease * treatment with corticosteroid,ig,immunosuppressive during 12 months.

Keywords: als bone marrow mesenchymal stem cell intravenous injection
zoledronic acid and positron emission tomography in treating patients with advanced non-small cell lung cancer

Conditions: Lung Cancer; Metastatic Cancer

Summary: rationale: a positron emission tomography scan is a procedure in which a small amount of radioactive sugar is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where tumor cells are found. this study is looking at whether the drug zoledronic acid interferes with the ability of a pet scan to find tumor cells. purpose: this phase ii trial is studying how well positron emission tomography works when given together with zoledronic acid in finding tumor cells in patients with advanced non-small cell lung cancer.

objectives: * determine the pet response rate after zoledronic acid in patients with non-small cell lung cancer. outline: patients receive 1 dose of zoledronic acid on day 1 followed by 3'-deoxy-3'-\[18f\]fluorothymidine/pet to determine standardized uptake value. projected accrual: a total of 12 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed non-small cell lung cancer * stage iiib (with pleural effusion) or stage iv disease * candidate for systemic therapy * measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral ct scan * no active brain metastases * more than 7 days since prior radiotherapy for brain metastases * must be neurologically stable with no seizures within the past 3 weeks patient characteristics: * ecog performance status (ps) 0-2 or karnofsky ps 60-100% * wbc ≥ 3,000/mm³ * anc ≥ 1,500/mm³ * platelet count ≥ 100,000/mm³ * bilirubin ≤ 1.5 times upper limit of normal (uln) * ast or alt ≤ 2.5 times uln (5 times uln if liver metastases present) * creatinine normal or creatinine clearance ≥ 60 ml/min by cockcroft-gault formula * no current active dental problems, including infection of the teeth or jawbone (maxilla or mandible) * no dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures * not pregnant * no uncontrolled intercurrent illness including, but not limited to, any of the following: * ongoing or active infection * symptomatic congestive heart failure * unstable angina pectoris * cardiac arrhythmia * psychiatric illness/social situations that would limit compliance with study requirements prior concurrent therapy: * see disease characteristics * no prior or other concurrent bisphosphonates * more than 2 weeks since prior surgery * more than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin c) and recovered * more than 7 days since prior palliative radiotherapy and recovered * more than 6 weeks since prior and no planned dental or jaw surgery * more than 30 days since prior participation in an investigational trial * no other concurrent investigational agent

Keywords: bone metastases stage iiib non-small cell lung cancer stage iv non-small cell lung cancer recurrent non-small cell lung cancer
choroidal blood flow and progression of age-related macular degeneration in the fellow eye in patients with unilateral choroidal neovascularisation

Conditions: Regional Blood Flow

Summary: age-related macular degeneration (amd) is the chief cause of severe and irreversible loss of vision in developed countries. the prevalence of amd increases dramatically with age. the early stage (or dry amd) is associated with minimal visual impairment and is characterized by large drusen and pigmentary abnormalities in the macula. the late stage is a neovascular, exudative form. this so called exudative amd includes serous or hemorrhagic detachment of retinal pigment epithelium and choroidal neovascularization leading to severe loss of vision (20/200 or worse). patients with unilateral cnv (choroidal neovascularisation) have a significant risk of cnv developing in the second eye. choroidal blood flow is of great importance for normal visual function. several reports have provided evidence suggesting that choroidal blood flow is decreased in subjects with amd. in late stages of amd angiogenesis leads to the formation of choroidal neovascularization that can cause severe visual impairment by disrupting normal macular function. the purpose of this evaluation is to investigate a possible link between alterations in choroidal blood flow and the development of cnv and serous detachment in the fellow eye of patients with amd and unilateral neovascular maculopathy. this longitudinal study may provide important findings with respect to natural history and visual prognosis of patients with neovascularized amd. ocular blood flow will be determined by non-invasive methods, including laser doppler flowmetry and laser interferometry


Eligibility criteria:
inclusion criteria: * male or female patients with unilateral choroidal neovascular amd and 2-4 risk factors for amd in the fellow eye. * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant ametropy \< 4 dpt. exclusion criteria: * abuse of alcoholic beverages * participation in a clinical trial in the 3 weeks preceding the study * any signs of diabetic retinopathy * glaucoma * symptoms of a clinically relevant illness in the 3 weeks before the first study day

Keywords: amd choroidal blood flow fellow eye in patients with unilateral choroidal neovascularisation
white matter plasticity in schizophrenia

Conditions: Schizophrenia Disorders

Summary: schizophrenia spectrum disorders are associated with impairment in the microstructure of white matter, the key brain tissue responsible for fast communication between different brain regions necessary for any complex task. this white matter impairment is linked to problems with cognition in schizophrenia, especially slower processing speed. this project aims to study the potential for correcting white matter deficits in schizophrenia by examining mechanisms underlying white matter structure changes in response to training on playing a mock musical instrument.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychosis nos * age 15-45 * able to provide informed consent exclusion criteria: * contraindications to mri (metal implants, claustrophobia) * medical condition that limits use of hands (ie, arthritis) * active or recent (within 6 months) substance use disorder other than nicotine

Keywords: music training plasticity